Department of Anaesthesia and Critical Care Medicine, Global Hospital, Lakdi-ka-pul, Hyderabad, Andhra Pradesh, India.
Ren Fail. 2010 Jan;32(1):69-73. doi: 10.3109/08860220903367502.
We sought to determine outcome and evaluate performance of Acute Physiology and Chronic Health Evaluation (APACHE) II and Sequential Organ Failure Assessment (SOFA) scores upon admission in predicting 30-day mortality of end-stage renal disease (ESRD) patients admitted in ICU.
This prospective observational cohort study examined 73 consecutive ESRD patients admitted in an ICU of a tertiary care institute over 15 months. Primary outcome measure was 30-day mortality. Data on patient characteristics, reason for ICU admission, cause of ESRD, mode of renal replacement, and use of mechanical ventilation (MV) or inotropes were recorded. The APACHE 2 and SOFA scores were calculated based on admission characteristics.
First-day median APACHE II, SOFA, and APACHE II-predicted hospital mortality rates were 26 (14-49), 7 (4-17), and 56.9% (18.6-97.4%), respectively. Observed ICU and 30-day mortality rates were 27.4%, and 41.1%, respectively. During the ICU course, MV and inotropic support was required in 27 (37%) and 23 (35.1%) patients, respectively. Need for MV (p < 0.001) and inotropic support (p < 0.001) were predictors of 30-day mortality in univariate analysis. Area under receiver operating characteristic curve for APACHE II in predicting 30-day mortality was 0.86 (95% CI, 0.76-0.93) compared with 0.92 (95% CI, 0.83-0.97) for SOFA score (p = 0.16).
Outcome of ESRD patients admitted to ICU is poor, especially if they require other organ support. APACHE II and SOFA scores perform well as predictors of 30-day mortality.
我们旨在确定急性生理学和慢性健康评估(APACHE)II 评分和序贯器官衰竭评估(SOFA)评分在入院时对预测 ICU 收治的终末期肾病(ESRD)患者 30 天死亡率的作用,并评估其效能。
这是一项前瞻性观察性队列研究,共纳入了 15 个月内在三级医疗机构 ICU 收治的 73 例 ESRD 患者。主要结局指标为 30 天死亡率。记录患者特征、入住 ICU 原因、ESRD 病因、肾脏替代治疗方式以及机械通气(MV)或正性肌力药物使用情况。根据入院特征计算 APACHE II 评分和 SOFA 评分。
第 1 天的中位数 APACHE II、SOFA 和 APACHE II 预测的住院死亡率分别为 26(14-49)、7(4-17)和 56.9%(18.6-97.4%)。观察到的 ICU 死亡率和 30 天死亡率分别为 27.4%和 41.1%。在 ICU 期间,27 例(37%)和 23 例(35.1%)患者需要接受 MV 和正性肌力药物支持。MV (p < 0.001)和正性肌力药物支持(p < 0.001)是单因素分析中 30 天死亡率的预测因素。APACHE II 预测 30 天死亡率的受试者工作特征曲线下面积为 0.86(95%CI,0.76-0.93),而 SOFA 评分的下面积为 0.92(95%CI,0.83-0.97)(p = 0.16)。
入住 ICU 的 ESRD 患者预后较差,尤其是需要其他器官支持的患者。APACHE II 评分和 SOFA 评分可较好地预测 30 天死亡率。